Shamburg News · 8-K filed Nov 12, 2026, 4:10 PM EST
Eledon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights
ELDN · Eledon Pharmaceuticals, Inc.
- Earnings
- Materiality: high
Eledon Pharmaceuticals reported a net loss of $3.9 million, or $0.03 per basic share, for the third quarter ended September 30, 2026, compared with a net loss of $17.5 million, or $0.21 per share, a year earlier. The quarter included a non-cash gain of $17.0 million from changes in the fair value of warrant liabilities. Cash, cash equivalents and short-term investments totaled $69.7 million at September 30, 2026, which the company expects will fund operations into Q2 2027.
Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001193125-26-458378.
Written from the filing by Shamburg Markets. Figures are as reported by the company.